Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and/or treating degenerative arthritis

A FGF-2, 1. The technology of FGF-2, applied in the field of biomedicine, can solve the problem of cartilage regeneration activity that has not been reported in the literature, and achieve the effects of low immunogenicity, easy synthesis, and broad application prospects

Pending Publication Date: 2020-07-03
LINK HEALTH GRP
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported in the literature that these two peptides can enhance osteoblast differentiation and new bone formation (see non-patent literature 6), but their cartilage regeneration activity has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and/or treating degenerative arthritis
  • Application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and/or treating degenerative arthritis
  • Application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and/or treating degenerative arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1, the solid-phase synthesis of peptide PDG6 and KED7

[0038] PDG6 (SEQ ID NO: 1) and KED7 peptide (SEQ ID NO: 2) were synthesized by a conventional solid-phase process, and the purity of the synthesized peptides was >95%. The HPLC detection profiles of the two peptides were as follows: Figure 1A and Figure 1B As shown, synthesize 500mg.

Embodiment 2

[0039] Example 2. The effect of peptide PDG6 and KED7 on the differentiation of mesenchymal stem cells in vitro

[0040] 1.1 Culture and passage of human mesenchymal stem cells: resuscitate human bone marrow mesenchymal stem cells (BMSCs, purchased from Guangzhou Saiye Biotechnology Co., Ltd.), add complete medium, and place at 37°C, 5% CO 2 cultured in a humidified incubator. On the second day after recovery, the recovered cells were replaced with fresh complete medium, and the cells were replaced with fresh complete medium every two days until the cells reached 80%-90% confluence, and then subcultured.

[0041] 1.2 Chondrogenic induction: The peptides PDG6 and KED7 were dissolved in phosphate buffered solution (PBS). Cells were resuspended in complete chondrogenic medium containing different concentrations of PDG6 or KED7 peptide (0.1 μM, 1 μM, and 10 μM) so that the concentration of BMSCs was 5.0 × 10 5 cells, and PBS was used as a negative control, and 1 μM human insulin...

Embodiment 3

[0047] Example 3. Effects of peptides PDG6 and KED7 on the proliferation of chondrocytes

[0048] 1.1 Chondrocyte culture: Cut the articular cartilage of 2-month-old New Zealand white rabbits under sterile conditions, cut into 1mm size, digest with 2mg / ml hyaluronidase for 45 minutes, 2mg / ml trypsin for 45 minutes, and 4mg / ml type II collagenase digested for 3 hours, washed and centrifuged (1500r / min) for 5 minutes, and the precipitate was placed in DMEM medium containing 15% fetal bovine serum for cultivation.

[0049] 1.2 Identification of chondrocytes: Take a small amount of primary chondrocyte smears and immunodetect with type I collagen antibody SABC, stained brownish yellow, indicating the secretion of type I collagen, and proved to be chondrocytes.

[0050] 1.3 MTS method to measure chondrocyte proliferation: chondrocytes were measured according to 2×10 4 Each well was inoculated in a 96-well plate, and different concentrations of peptides PDG6 and KED7 (0.1, 1, and 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of FGF-2 derived polypeptide to preparation of medicines for promoting cartilage repairing and / or treating degenerative arthritis. The FGF-2 derived polypeptideis polypeptide as shown in SEQID NO:1 or polypeptide as shown in SEQID NO:2. Peptide PDG6 and KED7 are from FGF-2, cartilage can be notably promoted to regenerate, and the FGF-2 derived polypeptide has favorable treatment effects on degenerative arthritis, besides, is easy to synthetize and low in immunogenicity, and has wide application prospects in treatment of cartilage injury and degenerativearthritis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the use of FGF-2 derived polypeptides in preparing medicines for promoting cartilage repair and / or treating osteoarthritis and medicines containing them. Background technique [0002] Osteoarthritis (OA) is a common joint disease, manifested as joint pain and stiffness, and cartilage damage is the main cause of osteoarthritis. Primary disease occurs frequently after middle age, and women are more than men, and the prevalence rate of 40-year-old crowd is 10%-17%, 50% over 60 years old, and up to 80% in 75-year-old crowd. The disability rate of the disease can be as high as 53%. With the aging population, osteoarthritis will become an important issue affecting people's quality of life, and the market demand for osteoarthritis drugs will continue to expand. [0003] At present, clinically, the therapeutic drugs for osteoarthritis are divided into specific therapeuti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61K31/728A61K45/06A61P19/02A61P19/04C07K19/00
CPCA61K38/1825A61K31/728A61K45/06A61P19/02A61P19/04C07K14/503C07K2319/30C07K2319/31A61K2300/00
Inventor 吴才梅许元生卢肖宇宋燕张时群
Owner LINK HEALTH GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com